Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Avadel Pharmaceuticals plc AVDL
$14.43
-$0.43 (-2.96%)
На 18:00, 12 мая 2023
-26.06%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1161551953.00000000
-
week52high
15.82
-
week52low
1.05
-
Revenue
0
-
P/E TTM
-7
-
Beta
1.43391000
-
EPS
-2.56000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 мар 2023 г. в 12:30
Описание компании
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 11 авг 2022 г. |
| Needham | Buy | Buy | 10 авг 2022 г. |
| Jefferies | Hold | Buy | 10 авг 2022 г. |
| Needham | Buy | Buy | 31 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 27 мая 2022 г. |
| Needham | Buy | Buy | 21 ноя 2022 г. |
| Jefferies | Buy | Hold | 30 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Palczuk Linda | D | 0 | 42000 | 20 янв 2023 г. |
| Palczuk Linda | A | 49900 | 2000 | 23 дек 2022 г. |
| MCHUGH THOMAS S | A | 76500 | 5000 | 29 ноя 2022 г. |
| Ende Eric J | A | 154900 | 20000 | 22 ноя 2022 г. |
| Glass Geoffrey Michael | D | 0 | 42000 | 05 авг 2022 г. |
| Ende Eric J | A | 42000 | 42000 | 03 авг 2022 г. |
| Glass Geoffrey Michael | A | 42000 | 42000 | 03 авг 2022 г. |
| McCamish Mark Anthony | A | 42000 | 42000 | 03 авг 2022 г. |
| Thornton Peter J. | A | 42000 | 42000 | 03 авг 2022 г. |
| Palczuk Linda | A | 42000 | 42000 | 03 авг 2022 г. |
Новостная лента
Why Shares of Avadel Soared This Week
The Motley Fool
05 мая 2023 г. в 15:44
Avadel said it plans to launch its lead therapy to treat excessive daytime sleepiness in adults with narcolepsy, in early June. The company had no revenue in the first quarter.
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
Seeking Alpha
19 апр 2023 г. в 08:20
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
GlobeNewsWire
10 апр 2023 г. в 08:00
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on Monday, April 17 at 9:30 a.m. ET.
Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call Transcript
Seeking Alpha
31 мар 2023 г. в 21:25
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior Vice President-Medical and Clinical Affairs Richard Kim – Chief Commercial Officer Tom McHugh – Chief Financial Officer Conference Call Participants Chris Howerton – Jefferies Adam Evertts – LifeSci Capital David Amsellem – Piper Sandler Matt Kaplan – Ladenburg Thalmann Operator Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations.
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
GlobeNewsWire
29 мар 2023 г. в 21:27
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022.